-
-
-
-
-
-
-
Solid Biosciences (SLDB) Misses Q1 EPS by 52c
-
-
-
-
-
-
-
Solid Biosciences (SLDB) halted, news pending
-
-
-
-
-
-
-
HHS adds duchenne muscular dystrophy to newborn screening panel
-
-
-
-
-
-
-
Solid Biosciences licenses gene therapy capsid to Kinea Bio
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Solid Biosciences (SLDB)
-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on Solid Biosciences (SLDB)
-
-
-
-
-
-
-
Solid Biosciences (SLDB) PT Raised to $20 at H.C. Wainwright
-
456,379 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

